Benzinga | Nov 15, 2021 11:09AM EST

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $29

Morgan Stanley maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $27 to $29.